IC-OS Working Group Webinar - Cardiac Amyloidosis: A Zebra or a Horse? Establishing the Correct Diagnosis

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Stockerl-Goldstein completed medical school at the UCLA School of Medicine. He trained in internal medicine, medical oncology and bone marrow transplantation at Stanford. He is a Professor of Medicine in the Section of BMT/Leukemia, Division of Oncology at Washington University School of Medicine in St. Louis where he serves as the Associate Program Director of the Hematology-Oncology Fellowship Program. He also serves as Co-Director of the Amyloid Center of Excellence. His areas of research include hematologic malignancies with a specific focus on plasma cell dyscrasias including light chain amyloidosis and multiple myeloma. He is a member of the NCCN Multiple Myeloma/Amyloidosis Guidelines Panel , the NCCN EHR Oncology Advisory Group and the ASBMT Informatics Committee.

Roberta Shcolnik Szor, is a hematologist at Sao Paulo Cancer Institute – University of Sao Paulo, Sao Paulo, Brazil.